LONDON – Neophore Ltd. announced the close of a $21 million series B that will enable it to further advance a portfolio of small-molecule DNA mismatch repair (MMR) inhibitors over the next 2.5 years.

Taiwanese researchers have elucidated the signaling mechanism downstream of IL-17 receptor B and shown that its blockade using a neutralizing antibody reduced pancreatic cancer tumorigenesis and metastasis, while prolonging the life of tumor-bearing mice.